JP2023544249A - リビトール治療 - Google Patents

リビトール治療 Download PDF

Info

Publication number
JP2023544249A
JP2023544249A JP2023515723A JP2023515723A JP2023544249A JP 2023544249 A JP2023544249 A JP 2023544249A JP 2023515723 A JP2023515723 A JP 2023515723A JP 2023515723 A JP2023515723 A JP 2023515723A JP 2023544249 A JP2023544249 A JP 2023544249A
Authority
JP
Japan
Prior art keywords
day
ribitol
dose
comprises administering
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544249A5 (https=
Inventor
ロン ルー,キー
ウー,ボー
Original Assignee
ザ シャーロット メクレンバーグ ホスピタル オーソリティー ディー/ビー/エー アトリウム ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ シャーロット メクレンバーグ ホスピタル オーソリティー ディー/ビー/エー アトリウム ヘルス filed Critical ザ シャーロット メクレンバーグ ホスピタル オーソリティー ディー/ビー/エー アトリウム ヘルス
Publication of JP2023544249A publication Critical patent/JP2023544249A/ja
Publication of JP2023544249A5 publication Critical patent/JP2023544249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Molecular Biology (AREA)
JP2023515723A 2020-09-10 2021-09-09 リビトール治療 Pending JP2023544249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076761P 2020-09-10 2020-09-10
US63/076,761 2020-09-10
PCT/US2021/049677 WO2022056137A1 (en) 2020-09-10 2021-09-09 Ribitol treatment

Publications (2)

Publication Number Publication Date
JP2023544249A true JP2023544249A (ja) 2023-10-23
JP2023544249A5 JP2023544249A5 (https=) 2024-09-11

Family

ID=80629815

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515723A Pending JP2023544249A (ja) 2020-09-10 2021-09-09 リビトール治療

Country Status (10)

Country Link
US (1) US20230364118A1 (https=)
EP (1) EP4210708A4 (https=)
JP (1) JP2023544249A (https=)
KR (1) KR20230069941A (https=)
CN (1) CN117355310A (https=)
AU (1) AU2021338706A1 (https=)
CA (1) CA3191582A1 (https=)
IL (1) IL301088A (https=)
MX (1) MX2023001881A (https=)
WO (1) WO2022056137A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10434113B2 (en) 2016-12-16 2019-10-08 The Charlotte Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
AU2020283556A1 (en) 2019-05-28 2022-01-06 The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health Compositions and methods of making ribitol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US20200061092A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245235B2 (en) * 2016-12-16 2019-04-02 The Charlotte-Mecklenburg Hospital Authority Compositions and methods for treating muscular dystrophy and other disorders
US20200061092A1 (en) * 2018-08-24 2020-02-27 The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health Methods and compositions for treating disorders associated with muscle weakness

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAT COMMUN, vol. 7:11534, JPN6025034027, 2016, ISSN: 0005672264 *
NAT COMMUN, vol. 9:3448, JPN6025034028, 2018, ISSN: 0005672263 *

Also Published As

Publication number Publication date
CA3191582A1 (en) 2022-03-17
AU2021338706A1 (en) 2023-05-25
CN117355310A (zh) 2024-01-05
EP4210708A1 (en) 2023-07-19
EP4210708A4 (en) 2024-10-23
WO2022056137A1 (en) 2022-03-17
IL301088A (en) 2023-05-01
MX2023001881A (es) 2023-04-03
US20230364118A1 (en) 2023-11-16
KR20230069941A (ko) 2023-05-19
WO2022056137A9 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
JP6612370B2 (ja) ポンペ病の処置のための投与計画
US12427161B2 (en) Methods for treating and pharmaceutical compositions
CN114929209A (zh) 肌萎缩侧索硬化的治疗
CZ292002B6 (cs) Léčivo pro snížení úmrtnosti způsobené městnavým selháním srdce u savců
CN103974619A (zh) 治疗法布里病的给药方案
JP7765970B2 (ja) ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法
BR112019025083A2 (pt) métodos de tratamento de pacientes portadores de fabry com insuficiência renal
CZ295567B6 (cs) Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus
CN117677395A (zh) 长效glp1/胰高血糖素受体激动剂的剂量方案
JP2023544249A (ja) リビトール治療
US20200061092A1 (en) Methods and compositions for treating disorders associated with muscle weakness
EP2806878A1 (en) Treatment of liver conditions
WO2012154779A1 (en) Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder
KR20250034995A (ko) 뉴클레오시드 의약품의 생체이용률을 증가시키는 방법
RU2653478C2 (ru) Способ улучшения функции печени
WO2012154892A1 (en) Combinations of propiverine and salivary stimulants for the treatment of overactive bladder
WO2012154893A1 (en) Combinations of trospium and salivary stimulants for the treatment of overactive bladder
WO2025212841A1 (en) Compositions and methods for treating diseases and disorders associated with muscle weakness
HK40112795A (en) Dosing regimens for the treatment of pompe disease
Boelaert et al. Antiretroviral treatment
EP2767287B1 (en) Agent for preventing or treating htlv-i associated myelopathy
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
HK40081935A (en) Treatment of amyotrophic lateral sclerosis
WO2012154778A1 (en) Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder
WO2012154775A1 (en) Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230330

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230426

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20230330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303